We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Voluminous Blood Transfusion Ineffectual in Hip Surgery

By HospiMedica International staff writers
Posted on 28 Dec 2011
Hip-fracture patients with an increased cardiovascular (CV) risk gained no survival or functional benefits from liberal use of blood transfusions, according to a new study.

Researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ; New Brunswick, USA) conducted a randomized trial involving 2,016 patients (50 years of age or older), who had either a history of or risk factors for CV disease, and whose hemoglobin level was below 10 g per deciliter after hip-fracture surgery. More...
The researchers randomly assigned patients to a liberal transfusion strategy, receiving a median of two units of red blood cells (RBCs), or a restrictive strategy, receiving 65% fewer units of blood, with half of the restrictive patients receiving no transfusions at all. The primary outcome was death or an inability to walk across a room without human assistance on 60-day follow-up.

The results showed that 35% of patients in the liberal-transfusion group met the primary endpoint, compared with 34.7% of patients randomized to the restrictive transfusion strategy. Additionally, 4.3% of the liberal-transfusion arm had an acute coronary syndrome or died in hospital, compared with 5.2% of patients in the restrictive-transfusion arm. The 60-day mortality was 7.6% with the liberal transfusion strategy and 6.6% with the restrictive strategy; complication rates also were similar between the two groups. The study was published ahead of print on December 14, 2011, in the New England Journal of Medicine (NEJM).

“It is reasonable to withhold transfusion in patients who have undergone surgery in the absence of symptoms of anemia or a decline in the hemoglobin level below 8 g per deciliter, even in elderly patients with underlying cardiovascular disease or risk factors,” concluded lead author Jeffrey Carson, MD, and colleagues. “A liberal transfusion strategy, as compared with a restrictive strategy, did not reduce rates of death or inability to walk independently on 60-day follow-up or reduce in-hospital morbidity in elderly patients at high cardiovascular risk.”

Related Links:

University of Medicine and Dentistry of New Jersey



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.